Craig-Hallum and KeyBanc lift OMCL price targets to $55 and $70 respectively following strong fiscal Q1 2026 results.
Omnicell (NASDAQ:OMCL) saw its price targets raised by two firms after reporting fiscal Q1 2026 earnings. Craig-Hallum increased its target to $55 from $53, citing a “beat and raise” quarter and long-term growth potential in AI-driven solutions like Titan and OmniSphere. The firm highlighted strong demand for demos and enterprise-wide adoption prospects.
KeyBanc also revised its target upward to $70 from $60, maintaining an Overweight rating. Omnicell provides medication management automation and adherence tools for healthcare systems, positioning itself for expansion in population health and point-of-care automation. Both firms reiterated bullish outlooks on the stock.
The upgrades follow Omnicell’s financial results released on April 28, which exceeded expectations and prompted analysts to emphasize the company’s innovation pipeline and market positioning.